Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Low-dose Trifluridine/Tipiracil With Bevacizumab in Refractory Metastatic Colorectal Cancer: a Multicenter, Single-arm, Phase 2 Study

NCT07085169 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT07085169
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07085169 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Low-dose Trifluridine/Tipiracil With Bevacizumab in Refractory Metastatic Colorectal Cancer: a Multicenter, Single-arm, Phase 2 Study
Lead sponsor
Ruijin Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
August 1, 2025
Completion date
August 1, 2028
Enrollment
50 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

bevacizumab, colo-rectal cancer, tas 102, third-line and beyond therapy